Pathway Genomics to participate in NASDAQ Fit Week

NASDAQ-2017-PR-Background-image

San Diego, CA – (BUSINESS WIRE) – January 2, 2017 — Pathway Genomics, an innovative commercial-stage genomics company, announced today that they will be participating in the 7th annual NASDAQ Fit Week. PathwayFit®, their test that assesses 80 genetic markers to help personalize and optimize diet, nutrition, metabolic health and exercise regimes, will be featured at Fit Week. As part of the event, Pathway will be offering PathwayFit® for a special price of $199 during the month of January and will also kick off the “This Is My Pathway” video contest to help create awareness about making informed, proactive lifestyle decisions.

“Pathway is proud of their partnership with NASDAQ and pleased to be a part of this event again in 2017,” said Jim Plante, Founder & CEO. “We are focused on providing genetic testing to help people better understand their propensity for risk so they are able to personalize their healthcare and make positive behavior changes that lead to improved overall health.”

To learn more about PathwayFit, visit http://www.pathway.com/fit-199 and to enter the This Is My Pathway video contest for a chance to win the $1000 Grand Prize visit http://www.pathway.com/thisismypathway.

About Pathway Genomics

Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The company’s program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Pathway believes in the power of “genetics first” to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.

PATHWAY GENOMICS CONTACTS:

 

Media, Press & Marketing:

Blythe Lawton, Senior Director, Marketing

858.568.7002

blythe.lawton@pathway.com

 

Investor Relations:

Kamal Adawi, Chief Financial Officer

858.900.3002

Kamal.Adawi@pathway.com

Comments are closed.